Major molecular response achievement in CML Patients can be predicted by BCR-ABL1/ABL1 or BCR-ABL1/GUS ratio at an earlier time point of follow-up than currently recommended. - Wikidata - awgldk - TriplyDB

Major molecular response achievement in CML Patients can be predicted by BCR-ABL1/ABL1 or BCR-ABL1/GUS ratio at an earlier time point of follow-up than currently recommended.

Major molecular response achievement in CML Patients can be predicted by BCR-ABL1/ABL1 or BCR-ABL1/GUS ratio at an earlier time point of follow-up than currently recommended.

http://www.wikidata.org/entity/Q34155213

about

Early BCR-ABL1 Transcript Decline after 1 Month of Tyrosine Kinase Inhibitor Therapy as an Indicator for Treatment Response in Chronic Myeloid Leukemia.Molecular genetic evaluation of myeloproliferative neoplasms.An analysis of the kinetics of molecular response during the first trimester of treatment with nilotinib in newly diagnosed chronic myeloid leukemia patients in chronic phase.Quantitative prediction of long-term molecular response in TKI-treated CML - Lessons from an imatinib versus dasatinib comparison BCR-ABL1 transcript levels at 4 weeks have prognostic significance for time-specific responses and for predicting survival in chronic-phase chronic myeloid leukemia patients treated with various tyrosine kinase inhibitors

P2860

Q36263943-E95EA1D3-5410-4839-9152-1D147FD08CF5 Q38481945-B5E522C2-3AB3-4B77-810E-D3BB989D5E75 Q46007169-124FD234-5D25-4FCA-806A-1A9D56016EFA Q58771228-315E051F-01A8-4407-9B9C-0513651F7DFB Q58778554-55405A26-FE73-4F75-90F0-23C6AE1F4679

P2860

Major molecular response achievement in CML Patients can be predicted by BCR-ABL1/ABL1 or BCR-ABL1/GUS ratio at an earlier time point of follow-up than currently recommended.

http://www.wikidata.org/entity/Q34155213

description

2014 nî lūn-bûn

@nan

2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Major molecular response achie ...... up than currently recommended.

@ast

Major molecular response achie ...... up than currently recommended.

@en

Major molecular response achie ...... up than currently recommended.

@nl

type

label

Major molecular response achie ...... up than currently recommended.

@ast

Major molecular response achie ...... up than currently recommended.

@en

Major molecular response achie ...... up than currently recommended.

@nl

prefLabel

Major molecular response achie ...... up than currently recommended.

@ast

Major molecular response achie ...... up than currently recommended.

@en

Major molecular response achie ...... up than currently recommended.

@nl

P1433

Q34155213-1D106EFB-E3CD-4355-AD81-B7F9B478A89D

P1476

Q34155213-BBEDC276-D068-4052-8AEE-B37FD9B5FB7B

P2093

Q34155213-39B864B5-8D76-4022-A928-19BA347E5D99

Q34155213-4EC410E6-C777-4A7A-95F3-80A48234DC4C

Q34155213-4F50EA58-082B-4AD0-A645-E12DE9489360

Q34155213-8D604830-864A-488F-AE1F-32E305FD0D99

Q34155213-96FFF5CD-A9B2-4D8C-8A19-B1BEFE6DBD81

Q34155213-AB5883B5-6E32-4A47-9005-0D316A22E16E

Q34155213-BB08935E-D68B-4BA3-BAC4-A39695F6A4BE

Q34155213-C11307D4-4B76-4D07-8499-27949A2AEE10

Q34155213-C66290FE-6BA7-4A3B-97CA-FA536A487EF2

Q34155213-DCFF9A52-0BB2-4142-932F-4D5EEB440035

P2860

Q34155213-102BE279-2C41-483A-80E4-93EE4133F5AE

Q34155213-15E746F7-C411-4806-AE90-BA028E768D6B

Q34155213-1CF77661-00FA-4204-BD28-754CB4E3E15B

Q34155213-26803A02-CAFB-4DB6-B022-704884952172

Q34155213-43746D01-FAF2-4D44-9FE3-81A871D3AD79

Q34155213-4FDE792C-AC24-4CA9-B281-919CDD80E6E0

Q34155213-59A81600-EB2A-4808-9DD1-BF9D6DFC488B

Q34155213-5BD21627-9B14-4611-9DF4-E82C7642BA55

Q34155213-610A10C4-D1F9-48FC-AE5E-9605F148C84A

Q34155213-676FFA39-73F8-4450-A218-4C7314C28E31

P304

Q34155213-74C1C622-B44F-4327-A94F-CFACD1DA847E

P31

Q34155213-A95DF94D-879B-422F-ACA9-F033EFDC8EE1

P356

Q34155213-7EBFFA8D-43E5-497B-B20C-360EC51D0A43

P407

Q34155213-D123D099-8006-4431-9588-C0239F2F895F

P433

Q34155213-CD6360D9-27AD-4801-A617-1E41ED890C98

P478

Q34155213-D932B6AF-1A52-45AE-94EC-1121D9037A22

P50

Q34155213-C46776C8-F837-4B51-A442-F860D9AB69CC

P577

Q34155213-7C37351D-9AA3-406A-AF80-24B76FA49D96

P5875

Q34155213-00DA1C37-149E-417F-9980-DCD5EE3CE9FB

P698

Q34155213-84EA7D45-8E75-4E24-990B-8D595042EA6A

P932

Q34155213-8A6CA3BA-27B5-4BA9-8480-6D6FC2A85068

P356

JOURNAL.PONE.0106250

P1433

P1476

Major molecular response achie ...... up than currently recommended.

@en

P2093

Amine Belhabri

http://www.w3.org/2001/XMLSchema#string

Denis Souche

http://www.w3.org/2001/XMLSchema#string

Franck Nicolini

http://www.w3.org/2001/XMLSchema#string

Isabelle Tigaud

http://www.w3.org/2001/XMLSchema#string

Jean-Pierre Magaud

http://www.w3.org/2001/XMLSchema#string

Mauricette Michallet

http://www.w3.org/2001/XMLSchema#string

Pascale Cony-Makhoul

http://www.w3.org/2001/XMLSchema#string

Sandrine Hayette

http://www.w3.org/2001/XMLSchema#string

Sarah Huet

http://www.w3.org/2001/XMLSchema#string

Sophie Gazzo

http://www.w3.org/2001/XMLSchema#string

P2860

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program.

Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION).

Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program.

Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)

Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results.

Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities

Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotini

P304

e106250

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0106250

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-09-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

265473372

http://www.w3.org/2001/XMLSchema#string

P698

25203717

http://www.w3.org/2001/XMLSchema#string

P932

4159116

http://www.w3.org/2001/XMLSchema#string